Goldman Sachs’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q1
Sell
-1,000
Closed -$29K 5859
2017
Q4
$29K Sell
1,000
-700
-41% -$22K ﹤0.01% 6052
2017
Q3
$46K Sell
1,700
-2,200
-56% -$48.7K ﹤0.01% 6269
2017
Q2
$82K Buy
3,900
+3,300
+550% +$69.7K ﹤0.01% 6200
2017
Q1
$11K Buy
600
+200
+50% +$3.15K ﹤0.01% 6601
2016
Q4
$6K Sell
400
-100
-20% -$1.36K ﹤0.01% 6804
2016
Q3
$7K Buy
+500
New +$5.8K ﹤0.01% 6903
2016
Q1
Sell
-450
Closed -$5K 7054
2015
Q4
$5K Buy
+450
New +$4.78K ﹤0.01% 7047

Other funds holding ACLS

Goldman Sachs's ACLS Position: Q2 2026 in Review

Goldman Sachs reduced its Axcelis (ACLS) stake by 53% in Q2 2026, selling an estimated $38.9M and leaving 235,253 shares worth $44.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1911.

Goldman Sachs first reported a position in ACLS in Q2 2013 and has held it in 53 quarters since. The position peaked at $99.9M in Q2 2024. 440 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Goldman Sachs held 235,253 shares of Axcelis worth $44.6M as of Q2 2026.
  • Goldman Sachs sold 262,371 Axcelis shares in Q2 2026, an estimated $38.9M.
  • Axcelis made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1911 holding.
  • Goldman Sachs first reported a position in Axcelis in Q2 2013 and has held it in 53 quarters since.
  • Goldman Sachs's Axcelis position peaked at $99.9M in Q2 2024.
  • 440 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.